DK0633893T3 - 17-Substituerede steroider, der er nyttige ved cancerbehandling - Google Patents
17-Substituerede steroider, der er nyttige ved cancerbehandlingInfo
- Publication number
- DK0633893T3 DK0633893T3 DK93906670T DK93906670T DK0633893T3 DK 0633893 T3 DK0633893 T3 DK 0633893T3 DK 93906670 T DK93906670 T DK 93906670T DK 93906670 T DK93906670 T DK 93906670T DK 0633893 T3 DK0633893 T3 DK 0633893T3
- Authority
- DK
- Denmark
- Prior art keywords
- carbon atoms
- beta
- hydrogen atom
- pyridyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929207057A GB9207057D0 (en) | 1992-03-31 | 1992-03-31 | Steroids |
GB929224880A GB9224880D0 (en) | 1992-11-27 | 1992-11-27 | Steroids |
PCT/GB1993/000531 WO1993020097A1 (en) | 1992-03-31 | 1993-03-15 | 17-substituted steroids useful in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0633893T3 true DK0633893T3 (da) | 2000-04-17 |
Family
ID=26300621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93906670T DK0633893T3 (da) | 1992-03-31 | 1993-03-15 | 17-Substituerede steroider, der er nyttige ved cancerbehandling |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0633893B1 (ko) |
JP (1) | JP2742331B2 (ko) |
KR (1) | KR100235135B1 (ko) |
AT (1) | ATE186913T1 (ko) |
AU (1) | AU668144B2 (ko) |
CA (1) | CA2132449C (ko) |
CZ (1) | CZ287434B6 (ko) |
DE (2) | DE69327096T2 (ko) |
DK (1) | DK0633893T3 (ko) |
ES (1) | ES2138618T3 (ko) |
GB (1) | GB2265624B (ko) |
IL (1) | IL105078A (ko) |
LU (1) | LU91911I2 (ko) |
MX (1) | MX9301525A (ko) |
NZ (1) | NZ249911A (ko) |
WO (1) | WO1993020097A1 (ko) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2170286C (en) * | 1993-09-30 | 2005-04-05 | Gerard Andrew Potter | Synthesis of 17-(3-pyridyl) steroids |
ATE177751T1 (de) * | 1993-10-27 | 1999-04-15 | Merrell Pharma Inc | Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren |
KR100725442B1 (ko) | 2000-11-17 | 2007-06-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 이미다졸 유도체, 이의 제조 방법 및 이의 용도 |
AU2002214320A1 (en) | 2000-11-20 | 2002-05-27 | Takeda Chemical Industries Ltd. | Imidazole derivatives, process for their preparation and their use |
AU2002221080A1 (en) | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
EP1463505A2 (en) * | 2001-12-13 | 2004-10-06 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
KR20050057086A (ko) * | 2002-08-28 | 2005-06-16 | 홀리스-에덴 파마슈티칼즈, 인코포레이티드 | 치료적 처치 방법 |
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
EP1781683B1 (en) | 2004-08-24 | 2011-11-16 | BTG International Limited | Process for the preparation of 17-vinyl- triflates as intermediates |
GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
DE102006008074B4 (de) * | 2006-02-22 | 2013-08-14 | RUHR-UNIVERSITäT BOCHUM | Behandlung von Krebs mit Geruchsrezeptor-Liganden |
CN104306977A (zh) | 2006-08-25 | 2015-01-28 | 库伽尔生物科技公司 | 治疗癌症的方法和组合物 |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
WO2009009132A1 (en) * | 2007-07-12 | 2009-01-15 | Cougar Biotechnology, Inc. | Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer |
US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
AU2010210422A1 (en) | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
MY155570A (en) | 2009-06-26 | 2015-10-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2011059969A2 (en) * | 2009-11-13 | 2011-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
WO2011088160A2 (en) * | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
WO2012018948A2 (en) | 2010-08-04 | 2012-02-09 | Pellficure Pharmaceuticals, Inc. | Novel treatment of prostate carcinoma |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
CN102558274B (zh) * | 2010-12-08 | 2014-10-15 | 深圳万乐药业有限公司 | 一种适合工业化生产醋酸阿比特龙的合成方法 |
WO2012083112A2 (en) * | 2010-12-16 | 2012-06-21 | Biomarin Pharmaceutical Inc. | Cyp11b, cyp17, and/or cyp21 inhibitors |
CN102558275A (zh) * | 2010-12-20 | 2012-07-11 | 天津药物研究院 | α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物 |
EP2702052B1 (en) | 2011-04-28 | 2017-10-18 | Novartis AG | 17alpha-hydroxylase/c17,20-lyase inhibitors |
DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102321142A (zh) * | 2011-09-29 | 2012-01-18 | 重庆医药工业研究院有限责任公司 | 一种醋酸阿比特龙晶型及其制备方法 |
PL2766381T3 (pl) | 2011-10-10 | 2016-12-30 | Sposób wytwarzania steroidów podstawionych w pozycji 17 | |
CN103059090B (zh) * | 2011-10-20 | 2016-06-22 | 连云港润众制药有限公司 | 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法 |
WO2013079964A1 (en) | 2011-11-30 | 2013-06-06 | Astrazeneca Ab | Combination treatment of cancer |
EP2607371A1 (en) | 2011-12-23 | 2013-06-26 | Crystal Pharma, S.A.U. | Processes for the preparation of abiraterone and related compouds |
CN103172690B (zh) * | 2011-12-23 | 2016-08-24 | 重庆医药工业研究院有限责任公司 | 醋酸阿比特龙及其中间体的制备方法 |
CN103193849B (zh) * | 2012-01-04 | 2016-05-04 | 连云港润众制药有限公司 | 一种高纯度醋酸阿比特龙的制备方法 |
CN103254265B (zh) | 2012-02-21 | 2016-07-13 | 上海希迈医药科技有限公司 | 醋酸阿比特龙三氟乙酸盐及其制备方法和应用 |
CN102627681B (zh) * | 2012-03-23 | 2016-04-13 | 山东新时代药业有限公司 | 一种醋酸阿比特龙的制备方法 |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
CA2871314A1 (en) * | 2012-04-23 | 2013-10-31 | Alphora Research Inc. | Process for preparation of 17-substituted steroids |
EP2858631A1 (en) | 2012-06-06 | 2015-04-15 | Novartis AG | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
CN102731605B (zh) * | 2012-06-19 | 2016-04-13 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙的纯化方法 |
US9512169B2 (en) * | 2012-07-10 | 2016-12-06 | Bayer Pharma Aktiengesellschaft | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
WO2014009436A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
WO2014009437A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
WO2014016830A1 (en) * | 2012-07-25 | 2014-01-30 | Mapi Pharma Ltd. | Process and intermediates for the preparation of abiraterone acetate |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
ITMI20121788A1 (it) | 2012-10-22 | 2014-04-23 | Olon Spa | Procedimento per la purificazione di abiraterone acetato |
WO2014071983A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making the 17-triflate intermediate of abiraterone-3-acetate |
WO2014071984A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making abiraterone-3-acetate |
TWI570131B (zh) * | 2012-11-13 | 2017-02-11 | 賽克系統公司 | 製備17-經取代類固醇之方法 |
WO2014075978A1 (en) | 2012-11-16 | 2014-05-22 | Synthon B.V. | Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound |
CN103059091B (zh) * | 2012-11-22 | 2017-04-19 | 常州靶点医药科技有限公司 | 一种避免重金属残留的醋酸阿比特龙的制备方法 |
CN103864878A (zh) * | 2012-12-12 | 2014-06-18 | 天津大学 | 阿比特龙醋酸酯的制备方法 |
EP2938625B1 (en) | 2012-12-31 | 2018-02-21 | Hetero Research Foundation | Process for the preparation of abiraterone acetate |
US20160022606A1 (en) | 2013-03-14 | 2016-01-28 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
BR112015023098A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Jefferson | agentes de infrarregulação do receptor de andrógeno e usos dos mesmos |
ES2612780T3 (es) | 2013-04-19 | 2017-05-18 | Zach System | Proceso para producir una forma sólida de acetato de abiraterona |
EP3013844A4 (en) * | 2013-06-24 | 2017-03-01 | Sun Pharmaceutical Industries LTD | Process for preparation of abiraterone acetate |
ITMI20131861A1 (it) * | 2013-11-08 | 2015-05-09 | Ind Chimica Srl | Processo per la preparazione di abiraterone e abiraterone acetato |
ES2581317T3 (es) | 2013-07-29 | 2016-09-05 | Industriale Chimica S.R.L. | Proceso de preparación de abiraterona o acetato de abiraterona |
ES2663469T3 (es) | 2013-07-29 | 2018-04-12 | Industriale Chimica S.R.L. | Proceso para la preparación de abiraterona y acetato de abiraterona |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
CN104558091B (zh) * | 2013-10-16 | 2017-07-28 | 天津金耀集团有限公司 | 一种醋酸阿比特龙的合成方法 |
WO2015114518A2 (en) * | 2014-01-28 | 2015-08-06 | Olon S.P.A. | Procedure for the preparation of abiraterone acetate and intermediates thereof |
CN103965282B (zh) | 2014-04-21 | 2016-01-20 | 武汉百科药物开发有限公司 | 一种醋酸阿比特龙的制备方法 |
US9315541B2 (en) | 2014-05-20 | 2016-04-19 | Olon S.P.A. | Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives |
WO2016001208A1 (en) | 2014-06-30 | 2016-01-07 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
CZ2014475A3 (cs) | 2014-07-09 | 2016-01-20 | Zentiva, K.S. | Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku |
US10093620B2 (en) | 2014-09-12 | 2018-10-09 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
MD3226843T2 (ro) | 2014-12-05 | 2021-10-31 | Aragon Pharmaceuticals Inc | Compoziții anticancer |
EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
WO2017133360A1 (zh) * | 2016-02-02 | 2017-08-10 | 深圳市塔吉瑞生物医药有限公司 | 一种甾体类化合物及包含该化合物的组合物及其用途 |
AU2017275396A1 (en) | 2016-06-03 | 2018-11-22 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
EP3528799A1 (en) | 2016-10-24 | 2019-08-28 | Pellficure Pharmaceuticals, Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
WO2019206472A1 (en) | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
HU231297B1 (hu) | 2018-07-31 | 2022-09-28 | Richter Gedeon Nyrt | Stabil gyógyszerkészítmények és eljárás az előállításukra |
CN110272465A (zh) * | 2019-07-15 | 2019-09-24 | 成都贝诺科成生物科技有限公司 | 阿比特龙衍生物、其制备方法与应用 |
CA3148115A1 (en) | 2019-08-08 | 2021-02-11 | Laekna Limited | Method of treating cancer |
EP3854384A1 (en) | 2020-01-27 | 2021-07-28 | Adamed Pharma S.A. | Pharmaceutical formulation comprising abiraterone acetate |
CA3177094A1 (en) | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
EP3944860A1 (en) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
WO2023148345A1 (en) | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
WO2023155846A1 (zh) * | 2022-02-18 | 2023-08-24 | 上海醇健医药技术有限公司 | 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1326234C (en) * | 1987-04-22 | 1994-01-18 | Michael R. Angelastro | 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors |
US4966898A (en) * | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
-
1993
- 1993-03-15 CA CA002132449A patent/CA2132449C/en not_active Expired - Lifetime
- 1993-03-15 ES ES93906670T patent/ES2138618T3/es not_active Expired - Lifetime
- 1993-03-15 WO PCT/GB1993/000531 patent/WO1993020097A1/en active IP Right Grant
- 1993-03-15 DE DE69327096T patent/DE69327096T2/de not_active Expired - Lifetime
- 1993-03-15 DK DK93906670T patent/DK0633893T3/da active
- 1993-03-15 AT AT93906670T patent/ATE186913T1/de active
- 1993-03-15 JP JP5517187A patent/JP2742331B2/ja not_active Expired - Lifetime
- 1993-03-15 CZ CZ19942337A patent/CZ287434B6/cs not_active IP Right Cessation
- 1993-03-15 KR KR1019940703426A patent/KR100235135B1/ko not_active IP Right Cessation
- 1993-03-15 GB GB9305269A patent/GB2265624B/en not_active Expired - Lifetime
- 1993-03-15 NZ NZ249911A patent/NZ249911A/en not_active IP Right Cessation
- 1993-03-15 EP EP93906670A patent/EP0633893B1/en not_active Expired - Lifetime
- 1993-03-15 AU AU37584/93A patent/AU668144B2/en not_active Expired
- 1993-03-16 IL IL105078A patent/IL105078A/xx active Protection Beyond IP Right Term
- 1993-03-18 MX MX9301525A patent/MX9301525A/es active IP Right Grant
-
2011
- 2011-12-07 LU LU91911C patent/LU91911I2/fr unknown
-
2012
- 2012-01-12 DE DE201212000012 patent/DE122012000012I1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2265624A (en) | 1993-10-06 |
CZ233794A3 (en) | 1995-02-15 |
KR950700923A (ko) | 1995-02-20 |
JP2742331B2 (ja) | 1998-04-22 |
CA2132449A1 (en) | 1993-10-14 |
NZ249911A (en) | 1996-06-25 |
CA2132449C (en) | 2002-09-10 |
AU668144B2 (en) | 1996-04-26 |
ATE186913T1 (de) | 1999-12-15 |
CZ287434B6 (en) | 2000-11-15 |
GB9305269D0 (en) | 1993-05-05 |
EP0633893B1 (en) | 1999-11-24 |
JPH07505377A (ja) | 1995-06-15 |
DE69327096T2 (de) | 2000-06-21 |
IL105078A0 (en) | 1993-07-08 |
DE122012000012I1 (de) | 2012-06-14 |
ES2138618T3 (es) | 2000-01-16 |
KR100235135B1 (ko) | 2000-01-15 |
EP0633893A1 (en) | 1995-01-18 |
DE69327096D1 (de) | 1999-12-30 |
MX9301525A (es) | 1994-02-28 |
AU3758493A (en) | 1993-11-08 |
GB2265624B (en) | 1995-04-19 |
IL105078A (en) | 1997-11-20 |
WO1993020097A1 (en) | 1993-10-14 |
LU91911I2 (fr) | 2012-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0633893T3 (da) | 17-Substituerede steroider, der er nyttige ved cancerbehandling | |
RU2210574C2 (ru) | Очищенные стероидсульфаматные соединения, эстрон-сульфаматы | |
KR950701527A (ko) | 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY) | |
GR3033524T3 (en) | Steroids which inhibit angiogenesis. | |
KR880012633A (ko) | C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물 | |
ATE128983T1 (de) | 17-spirofuran-3'-yliden steroide. | |
ZA906710B (en) | 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase | |
PT88648A (pt) | Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same | |
DE2960689D1 (en) | Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application | |
HUP0202595A2 (hu) | A 11-es helyzetben szénhidrogéncsoportot hordozó nem aromás ösztrogén szteroidok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
KR940701260A (ko) | 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법 | |
ZA805249B (en) | New amino-14 steriod derivatives and process for preparataion of the same | |
JPS5610200A (en) | Anthracycline glycoside* its manufacture and medicinal composition containing same for tumor treatment | |
ES8707518A1 (es) | Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol | |
GB989881A (en) | Improvements in or relating to 10 -methyl steroids and the production thereof | |
CA1266641C (en) | 16-keto-17-substituted thia-17-alkyl (or alkenyl or alkynyl) androstenes | |
GB905845A (en) | Steroid compounds and the preparation thereof | |
HUT42783A (en) | Process for preparing steroid aromatase-inhibitors | |
EP1196428A4 (en) | STEROIDS $ 11 g (b) -ARYL-17.17-SPIROTHIOLANE-SUBSTITUTED | |
TW343976B (en) | 17-substituted steroids useful in cancer treatment | |
GB1063663A (en) | Improvements in or relating to steroids and the manufacture thereof | |
WO1990015067A3 (fr) | NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES | |
ES403723A2 (es) | Un procedimiento para la preparacion de esteroides de la serie del pregnano | |
GB1099008A (en) | Novel unsaturated steroids, and processes for their preparation | |
GB961101A (en) | Steroid compounds |